BFM
NBIX icon

Boothbay Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

Boothbay Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,388
Closed -$1.9M – 2334
2025
Q4 		$1.9M Buy
+13,388
New +$1.94M 0.03% 581
2025
Q3 		– Sell
-16,932
Closed -$2.13M – 2056
2025
Q2 		$2.13M Buy
16,932
+14,132
+505% +$1.62M 0.04% 487
2025
Q1 		$310K Buy
+2,800
New +$355K 0.01% 1055
2024
Q4 		– Sell
-2,337
Closed -$269K – 1781
2024
Q3 		$269K Sell
2,337
-8,983
-79% -$1.23M 0.01% 1297
2024
Q2 		$1.56M Buy
+11,320
New +$1.55M 0.04% 581
2023
Q2 		– Sell
-36,624
Closed -$3.71M – 2119
2023
Q1 		$3.71M Buy
+36,624
New +$3.81M 0.08% 382
2022
Q3 		– Sell
-4,273
Closed -$417K – 2478
2022
Q2 		$417K Buy
+4,273
New +$394K 0.01% 1275
2022
Q1 		– Sell
-17,272
Closed -$1.46M – 2443
2021
Q4 		$1.47M Buy
17,272
+14,233
+468% +$1.31M 0.03% 596
2021
Q3 		$291K Sell
3,039
-393
-11% -$37.1K 0.01% 1352
2021
Q2 		$334K Buy
+3,432
New +$329K 0.01% 1221
2019
Q4 		– Sell
-29,100
Closed -$2.62M – 940
2019
Q3 		$2.62M Buy
+29,100
New +$2.72M 0.24% 101
2018
Q1 		– Sell
-4,190
Closed -$325K – 808
2017
Q4 		$325K Buy
+4,190
New +$286K 0.05% 405

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's NBIX Position: Q1 2026 in Review

Boothbay Fund Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 13,388 shares — an estimated $1.9M sold.

Boothbay Fund Management first reported a position in NBIX in Q4 2017 and held it in 12 quarters. The position peaked at $3.71M in Q1 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Boothbay Fund Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 13,388 Neurocrine Biosciences shares in Q1 2026, an estimated $1.9M.
  • Boothbay Fund Management first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 12 quarters.
  • Boothbay Fund Management's Neurocrine Biosciences position peaked at $3.71M in Q1 2023.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.